Solid Biosciences Inc. Payments to Acquire Marketable Securities
Solid Biosciences Inc. (SLDB) reported Payments to Acquire Marketable Securities of $401.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2020-05-07
- Solid Biosciences Inc. payments to acquire marketable securities for the quarter ending 2020-03-31 was $401.00K, a 97.40% decline year-over-year.
- Solid Biosciences Inc. payments to acquire marketable securities for the quarter ending 2019-03-31 was $15.42M.
| Period end | Payments to Acquire Marketable Securities 3 month |
|---|---|
| 2020-03-31 | $401.00K 10-Q · filed 2020-05-07 |
| 2019-03-31 | $15.42M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |